265 related articles for article (PubMed ID: 25496233)
1. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
[TBL] [Abstract][Full Text] [Related]
2. Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells.
Ebert R; Zeck S; Meissner-Weigl J; Klotz B; Rachner TD; Benad P; Klein-Hitpass L; Rudert M; Hofbauer LC; Jakob F
Bone; 2012 Mar; 50(3):723-32. PubMed ID: 22166808
[TBL] [Abstract][Full Text] [Related]
3. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
Mitrofan LM; Pelkonen J; Mönkkönen J
Bone; 2009 Dec; 45(6):1153-60. PubMed ID: 19699819
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro.
Räikkönen J; Crockett JC; Rogers MJ; Mönkkönen H; Auriola S; Mönkkönen J
Br J Pharmacol; 2009 Jun; 157(3):427-35. PubMed ID: 19371349
[TBL] [Abstract][Full Text] [Related]
5. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
Räikkönen J; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Pharmacol; 2010 Mar; 79(5):777-83. PubMed ID: 19819230
[TBL] [Abstract][Full Text] [Related]
6. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
[TBL] [Abstract][Full Text] [Related]
7. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
[TBL] [Abstract][Full Text] [Related]
10. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid-induced IPP/ApppI production in vivo.
Mönkkönen H; Ottewell PD; Kuokkanen J; Mönkkönen J; Auriola S; Holen I
Life Sci; 2007 Sep; 81(13):1066-70. PubMed ID: 17850825
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates induce breast cancer cell death in vitro.
Fromigue O; Lagneaux L; Body JJ
J Bone Miner Res; 2000 Nov; 15(11):2211-21. PubMed ID: 11092402
[TBL] [Abstract][Full Text] [Related]
13. Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.
Journé F; Kheddoumi N; Chaboteaux C; Duvillier H; Laurent G; Body JJ
Breast Cancer Res; 2008; 10(1):R4. PubMed ID: 18190680
[TBL] [Abstract][Full Text] [Related]
14. Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry.
Jauhiainen M; Mönkkönen H; Räikkönen J; Mönkkönen J; Auriola S
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):2967-75. PubMed ID: 19665949
[TBL] [Abstract][Full Text] [Related]
15. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
16. Uptake of free, calcium-bound and liposomal encapsulated nitrogen containing bisphosphonates by breast cancer cells.
Zlatev HP; Auriola S; Mönkkönen J; Määttä JA
Eur J Pharm Sci; 2016 Apr; 86():58-66. PubMed ID: 26957415
[TBL] [Abstract][Full Text] [Related]
17. Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells.
Ashihara E; Munaka T; Kimura S; Nakagawa S; Nakagawa Y; Kanai M; Hirai H; Abe H; Miida T; Yamato S; Shoji S; Maekawa T
Biochem Biophys Res Commun; 2015 Aug; 463(4):650-5. PubMed ID: 26047704
[TBL] [Abstract][Full Text] [Related]
18. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
[TBL] [Abstract][Full Text] [Related]
19. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
20. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
